271 related articles for article (PubMed ID: 18622894)
1. Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma.
Broecker-Preuss M; Sheu SY; Worm K; Feldkamp J; Witte J; Scherbaum WA; Mann K; Schmid KW; Schott M
Horm Metab Res; 2008 Oct; 40(10):685-91. PubMed ID: 18622894
[TBL] [Abstract][Full Text] [Related]
2. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach.
Murakawa T; Tsuda H; Tanimoto T; Tanabe T; Kitahara S; Matsubara O
Pathol Int; 2005 Dec; 55(12):757-65. PubMed ID: 16287490
[TBL] [Abstract][Full Text] [Related]
3. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
4. C-kit expression and mutational analysis in medulloblastoma.
Chilton-Macneill S; Ho M; Hawkins C; Gassas A; Zielenska M; Baruchel S
Pediatr Dev Pathol; 2004; 7(5):493-8. PubMed ID: 15547773
[TBL] [Abstract][Full Text] [Related]
5. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
6. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
7. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.
Boldrini L; Ursino S; Gisfredi S; Faviana P; Donati V; Camacci T; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4101-8. PubMed ID: 15217946
[TBL] [Abstract][Full Text] [Related]
8. C-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis.
Tayal S; Classen E; Bemis L; Robinson WA
Anticancer Res; 2005; 25(3B):2215-20. PubMed ID: 16158966
[TBL] [Abstract][Full Text] [Related]
9. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
10. Absence of gene mutations in KIT-positive carcinoma showing thymus-like elements of the thyroid.
Pan Y; Zhao X; Yang J; Deng J; Zhan Z; Luo Y; Li Q; Guo Y; Zhai Q; Sun B
Hum Pathol; 2012 Mar; 43(3):350-5. PubMed ID: 21835435
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-kit proto-oncogene product in breast tissue.
Yared MA; Middleton LP; Meric F; Cristofanilli M; Sahin AA
Breast J; 2004; 10(4):323-7. PubMed ID: 15239791
[TBL] [Abstract][Full Text] [Related]
12. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features.
Tsuda H; Tani Y; Weisenberger J; Kitada S; Hasegawa T; Murata T; Tamai S; Hirohashi S; Matsubara O; Natori T
Cancer Sci; 2005 Jun; 96(6):333-9. PubMed ID: 15958055
[TBL] [Abstract][Full Text] [Related]
13. Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas.
Ensinger C; Prommegger R; Kendler D; Gabriel M; Spizzo G; Mikuz G; Kremser R
Anticancer Res; 2003; 23(3B):2349-53. PubMed ID: 12894514
[TBL] [Abstract][Full Text] [Related]
14. OCT4 expression on a case of poorly differentiated (insular) carcinoma of the thyroid gland and minireview.
Ruangpratheep C; Lohachittranond C; Poonpracha T; Punyarit P
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S281-9. PubMed ID: 16858970
[TBL] [Abstract][Full Text] [Related]
15. C-kit gene mutation: common and widely distributed in intracranial germinomas.
Kamakura Y; Hasegawa M; Minamoto T; Yamashita J; Fujisawa H
J Neurosurg; 2006 Mar; 104(3 Suppl):173-80. PubMed ID: 16572634
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
Uccini S; Mannarino O; McDowell HP; Pauser U; Vitali R; Natali PG; Altavista P; Andreano T; Coco S; Boldrini R; Bosco S; Clerico A; Cozzi D; Donfrancesco A; Inserra A; Kokai G; Losty PD; Nicotra MR; Raschellà G; Tonini GP; Dominici C
Clin Cancer Res; 2005 Jan; 11(1):380-9. PubMed ID: 15671569
[TBL] [Abstract][Full Text] [Related]
17. Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues.
Ito Y; Yoshida H; Nakano K; Kobayashi K; Yokozawa T; Hirai K; Matsuzuka F; Matsuura N; Kuma K; Miyauchi A
Int J Mol Med; 2002 Apr; 9(4):373-6. PubMed ID: 11891530
[TBL] [Abstract][Full Text] [Related]
18. p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma.
Matias-Guiu X; Villanueva A; Cuatrecasas M; Capella G; De Leiva A; Prat J
Pathol Res Pract; 1996 Dec; 192(12):1242-9; discussion 1250-1. PubMed ID: 9182295
[TBL] [Abstract][Full Text] [Related]
19. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.
Sengupta S; Cheville JC; Corless CL; Lohse CM; Heinrich MC; Kwon ED; Zincke H; Blute ML; Leibovich BC
J Urol; 2006 Jan; 175(1):53-6. PubMed ID: 16406868
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer.
Chakravarty G; Santillan AA; Galer C; Adams HP; El-Naggar AK; Jasser SA; Mohsin S; Mondal D; Clayman GL; Myers JN
Exp Biol Med (Maywood); 2009 Apr; 234(4):372-86. PubMed ID: 19176870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
